A5015470174- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Immunodeficiency and Autoimmune Disorders
- Helicobacter pylori-related gastroenterology studies
- Celiac Disease Research and Management
- Gut microbiota and health
- Diverticular Disease and Complications
- Pregnancy and Medication Impact
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal motility and disorders
- Biosimilars and Bioanalytical Methods
- Clostridium difficile and Clostridium perfringens research
- Liver Diseases and Immunity
- Autoimmune and Inflammatory Disorders Research
- Diagnosis and treatment of tuberculosis
- Systemic Lupus Erythematosus Research
- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Adolescent and Pediatric Healthcare
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Screening and Detection
Icahn School of Medicine at Mount Sinai
2016-2025
Mount Sinai Hospital
2013-2025
Mount Sinai Hospital
2015-2025
Inserm
2005-2024
University of Calgary
2007-2024
McGill University Health Centre
2024
Mount Sinai Hospital
2015-2024
Mount Sinai Medical Center
2005-2023
Centre Hospitalier Universitaire de Lille
2008-2021
Leona M. and Harry B. Helmsley Charitable Trust
2021
Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis.Two randomized, double-blind, placebo-controlled studies--the Active Ulcerative Colitis Trials 1 and 2 (ACT ACT 2, respectively)--evaluated the efficacy of infliximab induction maintenance therapy in adults with colitis. In each study, 364 patients moderate-to-severe active colitis despite concurrent medications received placebo...
The comparative efficacy and safety of infliximab azathioprine therapy alone or in combination for Crohn's disease are unknown.
Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis.We conducted two integrated randomized, double-blind, placebo-controlled trials in patients with active disease. In the trial induction therapy, 374 (cohort 1) received (at a dose 300 mg) or placebo intravenously at weeks 0 and 2, 521 2) open-label disease evaluation week 6. maintenance either cohort who had response to 6 were randomly assigned continue receiving every 8...
The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown.In integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) adults active disease. In the trial, 368 patients were randomly assigned to receive or placebo at weeks 0 2 (cohort 1), 747 received open-label 2); status was week 6. 461 who had a response every 8 4 until 52.At 6, total 14.5% cohort 1 6.8% clinical remission (i.e., score on Disease...
This paper is the second in a series of three publications relating to European evidence-based consensus on diagnosis and management Crohn's disease concerns active disease, maintenance medically induced remission surgery. The aims methods ECCO Consensus, as well sections classification are covered first [van Assche et al. JCC 2009a]. final covers post-operative recurrence, fistulating paediatric adolescent IBD, pregnancy, psychosomatics, extraintestinal manifestations complementary or...
Background: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF infliximab. No anti-TNF agent has been evaluated prospectively in had responded another and then lost that response or were intolerant of agent. Objective: To determine whether adalimumab induces remissions more frequently than placebo adult have symptoms despite infliximab therapy cannot take because adverse events. Design:...
Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue.We conducted two controlled trials to evaluate natalizumab as induction maintenance therapy in patients with active Crohn's disease. In the first trial, 905 were randomly assigned receive 300 mg of or placebo at weeks 0, 4, 8. The primary outcome was response, defined by decrease Disease Activity Index (CDAI) score least 70 points, week 10. second 339 who had...
What makes an IBD patient immunocompromised?From genome wide association studies there is increasing evidence of aberrant immune response in IBD. 4 Susceptibility loci involve both the innate and adaptive towards a diminished diversity commensal microbiota. 5Description numerous mechanisms contributing to this dysimmunity beyond scope article.Despite defective mucosal immunity, no proof systemic defect patients with absence concomitant immunomodulator therapy.Patients are therefore rendered...